Phase I/II study of HSP90 inhibitor AUY922 and Erlotinib for EGFR-Mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Drug Resistance, Neoplasm
  • HSP90 Heat-Shock Proteins
  • Isoxazoles
  • Lung Neoplasms
  • Quinazolines
  • Resorcinols

abstract

  • Partial responses were observed, but the duration of treatment with AUY922 and erlotinib was limited by toxicities, especially night blindness. This phase II study of AUY922 and erlotinib did not meet its primary end point.

publication date

  • May 20, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4881377

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.59.7328

PubMed ID

  • 25870087

Additional Document Info

start page

  • 1666

end page

  • 73

volume

  • 33

number

  • 15